Semax Dosage: A Complete and Reliable Guide

What is a reasonable starting dose of Semax?

Let's be honest about something important before we get to the numbers: there is no officially established, FDA-approved starting dose of Semax for humans, as Semax has never gone through Western clinical trial dosing protocols.

What exists is an extensive body of Russian clinical and animal research providing a reasonable picture of the doses that have actually been tested and used. In published Russian clinical literature, intranasal doses for stroke patients have ranged from 12 to 18 milligrams per day [1], while many smaller animal behavior and cognitive studies have used substantially lower doses, in the range of 0.05–0.5 milligrams per kilogram of body weight [2], [3]. This is a fairly wide range and the appropriate dose really depends on what one is trying to achieve and which body of research one is referring to.

For someone new to using Semax, the general rule seen in research — and followed by most people in the nootropic communities — is to start with a low dose and observe the body's reaction before increasing it. Animal studies consistently show that Semax does not follow a simple „more is better” pattern. In one anti-hypoxic study, the effects of Semax actually followed a bell-shaped curve rather than a straight line — efficacy increased with the dose up to a certain point and then began to decrease at higher doses [4]. This is an important detail because it tells us that increasing the dose does not necessarily provide more benefits, and finding your own lower effective range matters more with Semax than with some other compounds.

What counts as a minimal effective dose?

Based on available research, even fairly small doses elicited measurable effects. In rat studies analyzing BDNF and gene expression changes, a single intranasal dose of just 50 micrograms per kilogram of body weight was sufficient to induce a significant increase in hippocampal BDNF [5]. When extrapolated to human conditions, such microgram-per-kilogram dosing translates to a relatively small total dose. However, it's important to emphasize that extrapolating animal doses to human conditions is not a simple multiplication and should not be treated as such.

Essentially, this tells us that Semax doesn't seem to require large amounts to start eliciting biological effects. Early Russian clinical work on cognitive and attentional benefits in healthy individuals used doses in the range of 0.015–0.050 milligrams per kilogram of body weight, administered intranasally [6]. For an average adult, this translates to a range of approximately 1–4 milligrams. This provides a reasonable benchmark for a minimum effective dose based on historical clinical work, although no formal dose-ranging study has established the exact threshold.

How to increase the dose over time?

If starting from scratch, the most sensible approach based on available pharmacology is to begin at the lower end of the researched range, give the body several days to show how it responds, and only increase the dose gradually as needed—rather than jumping straight to the higher doses used in clinical stroke protocols. Stroke patients receiving 12–18 milligrams daily [1] were dealing with a serious medical condition under physician supervision, and that context simply doesn't apply to an individual using Semax for general cognitive support.

A gradual approach also makes sense, considering that Semax's effects accumulate over time at the gene expression level, rather than appearing immediately. Researchers tracking the gene expression of BDNF and NGF after a single dose found a complex, changing pattern over subsequent hours—levels rose and fell at different time points in different brain regions [7]. This tells us that Semax is doing something dynamic and continuous in the body, rather than simply providing a one-off boost. Allowing yourself to observe your own reaction over several days, rather than rapidly escalating, fits this slower, more layered biological picture.

Is there a reliable Semax dosage calculator?

There is no official, scientifically validated Semax dosing calculator, and any calculator found online is built on extrapolated animal data and user-reported practices, not human dose-finding studies.

However, the basic math behind reconstitution and dosing is straightforward once a concentration and target dose are established. If a vial contains, for instance, 10 milligrams of Semax powder and is reconstituted with 2 milliliters of bacteriostatic water, this yields a concentration of 5 milligrams per milliliter, or 5000 micrograms per milliliter. From here, calculating how many milliliters corresponds to a 300 microgram dose is simple division. What no calculator can responsibly establish, however, is what dose anyone should actually be aiming for, as that number simply has not been established by controlled human trials.

What does the Semax dosage table actually look like?

Below is a practical summary of dosage ranges that have actually appeared in published studies, organized by context. It's worth reiterating that none of these represent an officially approved dosing protocol for humans—they reflect what has been investigated and used under specific research and clinical conditions.

This range is wide, as the appropriate dose truly depends largely on what condition is being treated, and how severe it is. Stroke recovery protocols are on the upper end of the scale, as they treat severe neurological injury, whereas general cognitive studies in healthy animals and humans focus on the lower end.

How many puffs per dose does that translate to?

It entirely depends on the concentration of the specific product, as a single spray is not a standardized unit — it differs depending on the bottle's design and the atomizer's nozzle. As a general reference point, a standard nasal spray pump actuation typically delivers about 100 microliters, though this can vary.

For the 1% solution — 10 milligrams per milliliter, or 10,000 micrograms per milliliter — a single 100-microliter spray would deliver approximately 1,000 micrograms, or 1 milligram. With a 0.1% solution—1 milligram per milliliter—the same volume of spray would deliver approximately 100 micrograms.

This is precisely why concentration is so important for dosing accuracy. The same number of sprays can mean drastically different actual doses depending on the strength of the solution being used. Every person using a nasal spray product needs to know both the concentration of their specific bottle and the volume of a single actuation from their specific nozzle to have real confidence in their dose—which partly explains why nasal administration, while convenient, is indeed less precise than injection.

What does the Semax and Selank combination dosage table look like?

There are no published clinical trials establishing a formal dosing table for the combination of Semax and Selank together, as no controlled studies have tested them as a combined protocol.

What exists in practice is simply dosing each peptide according to its individually studied range, administered together or at different times of the day. Selank's own studies typically used doses in a similar microgram-to-low-milligram range as Semax [12], and in Russian clinical use, the two peptides are typically formulated and dosed as separate nasal solutions, rather than as a single combined product. Anyone combining them is essentially imposing two individually dosed protocols, rather than following any validated co-administration regimen.

How often should Semax actually be taken?

Once daily is the frequency most consistently observed in both human and animal studies, and it aligns well with what is known about Semax's duration of action. Early Russian clinical work specifically noted that the cognitive and performance benefits of a single intranasal dose lasted for about 20–24 hours [6], naturally supporting a once-daily dosing schedule rather than multiple doses spread throughout the day. If the effects of a morning dose are still significantly present 20 or more hours later, there is no obvious pharmacological reason to dose again before this window closes.

However, some clinical protocols involved administration spread throughout the day, rather than a single dose. In post-stroke rehabilitation studies, a total daily dose of 6000 micrograms was delivered as part of structured 10-day treatment courses [10], and the precise timing within the day—single versus divided doses—was not always specified in detail in published summaries. A practical conclusion is that once-daily dosing has a solid basis in available evidence, but dividing the daily dose into two smaller administrations is also consistent with how it has been used clinically in some contexts.

Can Semax be taken daily on a continuous basis?

This is truly one of the more important open questions in Semax literature, and the honest answer is that data on long-term continuous use simply doesn't exist.

What exists is a strong pattern in Russian clinical practice of using Semax in specified courses, rather than indefinite daily use—typically 10-day treatment blocks with a break, sometimes repeated after a few weeks [10]. This cyclical approach, rather than continuous daily use stretched over months or years, is the model with the greatest clinical precedent behind it.

There is also a reasonable biological argument for this cyclical approach. Since a significant portion of Semax's benefits appear to stem from inducing changes in gene expression and neurotrophin production – rather than from continuous receptor occupation itself [5], [7] – it is plausible that intermittent, cyclical dosing allows these biological cascades to fully develop and then reset, rather than potentially blunting the response through constant, uninterrupted stimulation. This is reasoning from an available mechanism, rather than a directly tested outcome, but it helps to explain why the cyclical approach has become standard practice, rather than indefinite daily use.

What is a reasonable dosing regimen to use?

Based on how Semax has actually been used in existing research, a reasonable structure looks like this: a single intranasal dose per day, taken in the morning due to the peptide's more activating profile, for a specified period of around 10–14 days, followed by a break of several weeks before potential re-administration. This mirrors the structure used in Russian post-stroke rehabilitation protocols [10] and several chronic animal studies that typically lasted one to two weeks, rather than months [13].

This is not a rigid rule based on controlled human trials—it is a pattern that emerges from a review of the entire available research base. Anyone using Semax outside of medical supervision should treat this as a general framework, not a precise prescription, and pay close attention to their own body's response, rather than assuming a set schedule will work identically for everyone.

Does the frequency need to change depending on the purpose?

It's reasonable to believe so, although no study has directly tested different frequencies against each other for different purposes.

Stroke recovery protocols, including for more severe neurological injury, used higher total doses delivered across structured 10-day courses [1], [10]—a more intensive schedule than that typically used in lower-dose cognitive and behavioral trials [2], [6]. This suggests that more demanding clinical targets were paired with more frequent, higher-intensity dosing regimens, whereas lighter cognitive support applications typically involved smaller, simpler dosing.

For someone using Semax for general cognitive enhancement, rather than treating a specific medical condition, there is no evidence to suggest that dosing more frequently than once daily would add significant benefits. Given the bell-shaped dose-response pattern observed in some studies [4], more does not automatically equate to better. Starting with a simple once-daily regimen and adjusting based on observed personal response is a more rational approach than assuming a more aggressive schedule will yield proportionally better outcomes.

Disclaimer

This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or self-administration dosing instructions. Semax remains an investigational compound in most countries, including the United States and most European countries, and is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. Dosing information presented here reflects amounts studied or used in published research and clinical practice and is not intended to guide or encourage self-administration. There is no officially validated dosing protocol for humans outside of Russian clinical practice. Additional, well-designed clinical trials are needed to more broadly establish safe and effective dosing in humans.

References

[1] Gusev, E. I., Skvortsova, V. I., Myasoedov, N. F., Nezavibatko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of semax in acute period of hemispheric ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 97(6), 26–34. PMID: 11517472

[2] Inozemtsev, A. N., Agapitova, A. E., Bokieva, S. B., Glazova, N. Yu., Levitskaia, N. G., Kamenskiĭ, A. A., & Miasoedov, N. F. (2013). Opposite Semax influence on conditioning and functional disturbances of avoidance responses in rats. Journal of Higher Nervous Activity named after I. P. Pavlov, 63(6), 711–718. https://doi.org/10.7868/s0044467713060063

[3] Levitskaya, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Yu., Kamenskii, A. A., & Myasoedov, N. F. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system. Neuroscience and Behavioral Physiology, 34(4), 399–405. https://doi.org/10.1023/b:neab.0000018752.59465.28

[4] Iasnetsov, Vik. V., & Voronina, T. A. (2010). Antihypoxic and antiamnesic effects of mexidol and semax. Experimental and Clinical Pharmacology, 73(4), 2–7. PMID: 20486550

[5] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108

[6] Ashmarin, I. P., Nezavibat’ko, V. N., Miasoedov, N. F., Kamenskiĭ, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745

[7] Shadrina, M., Kolomin, T., Agapova, T., Agniullin, Y., Shram, S., Slominsky, P., Lymborska, S., & Myasoedov, N. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41(1), 30–35. https://doi.org/10.1007/s12031-009-9270-z

Dolotov, O. V., Karpenko, E. A., Seredenina, T. S., Inozemtseva, L. S., Levitskaya, N. G., Zolotarev, Yu. A., Kamensky, A. A., Grivennikov, I. A., Engele, J., & Myasoedov, N. F. (2006). Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 97(Suppl 1), 82–86. https://doi.org/10.1111/j.1471-4159.2006.03658.x

[9] Levitskaya, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Yu., Kamenskii, A. A., & Myasoedov, N. F. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system. Neuroscience and Behavioral Physiology, 34(4), 399–405. https://doi.org/10.1023/b:neab.0000018752.59465.28

Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68

[11] Polunin, G. S., Nurieva, S. M., Baiandin, D. L., Sheremet, N. L., & Andreeva, L. A. (2000). Evaluation of the therapeutic effect of the new Russian drug semax in optic nerve disease. Ophthalmology Journal, 116(1), 15–18. PMID: 10741256

[12] Yasenyavskaya, A. L., Samotrueva, M. A., Tsibizova, A. A., Bashkina, O. A., Myasoedov, N. F., & Andreeva, L. A. (2021). The influence of Selank on the level of cytokines under the conditions of „social” stress. Current Reviews in Clinical and Experimental Pharmacology, 16(2), 162-167. https://doi.org/10.2174/1574884715666200704152810

[13] Vilenskiĭ, D. A., Levitskaia, N. G., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2007). Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats. Sechenov Physiological Journal of Russia, 93(6), 661–669. PMID: 17850024